Preview

Современная ревматология

Расширенный поиск

Эффективность ритуксимаба при железистых формах болезни Шёгрена по результатам международных клинических исследований

https://doi.org/10.14412/1996-7012-2020-1-85-92

Полный текст:

Аннотация

Болезнь Шёгрена (БШ) – хроническое аутоиммунное заболевание, характеризующееся лимфоплазмоцитарной инфильтрацией экзокринных желез, ведущей к развитию их деструкции и прогрессирующей функциональной недостаточности. Распространенность БШ составляет около 5%, что делает ее одним из наиболее часто встречающихся аутоиммунных заболеваний. БШ зачастую имеет хроническое, медленно прогрессирующее течение.

В статье обсуждаются результаты международных клинических исследований, посвященных эффективности анти-В-клеточной терапии ритуксимабом (РТМ) при железистых формах БШ. Рассмотрено влияние данной терапии на различные иммунологические, гистологические показатели, субъективные и объективные параметры функции желез и активность заболевания. Обсуждаются возможные причины несоответствия результатов открытых клинических исследований и рандомизированных клинических испытаний, а также предикторы эффективности терапии ритуксимабом.

Установлено, что РТМ при БШ эффективно снижает В-клеточную активность, улучшает морфологическую картину в слюнных железах и некоторые внежелезистые проявления заболевания, уменьшает сухость и слабость. Отмечается большой потенциал анти-В-клеточных препаратов в терапии БШ. 

Об авторе

А. В. Торгашина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, , Москва, Каширское шоссе, 34А


Литература

1. Сафонова ТН, Васильев ВИ, Лихванцева ВГ. Синдром Шегрена: Руководство для врачей. Москва: Издательство Московского университета; 2013.

2. Patel R, Shahane A. The epidemiology of Sjö gren's syndrome. Clin Epidemiol. 2014;6:247-55. doi: 10.2147/CLEP.S47399

3. Brito-Zeron P, Baldini C, Bootsma H, et al. Sjö gren syndrome. Nat Rev Dis Primer. 2016;2:16047. doi: 10.1038/nrdp.2016.47

4. Solans-Laque R, Lopez-Hernandez A, Angel Bosch-Gil J, et al. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjö gren's syndrome. Semin Arthritis Rheum. 2011;41:415-23. doi: 10.1016/j.semarthrit.2011.04.006

5. Логвиненко ОА, Васильев ВИ. Неходжкинские лимфомы при ревматических заболеваниях. Научно-практическая ревматология. 2011;49(5):71-82. doi: 10.14412/1995-4484-2011-1464.

6. Gottenberg JE, Ravaud P, Puchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjö gren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312(3):249-58. doi: 10.1001/jama.2014.7682

7. Brito-Zeron P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjö gren's syndrome. Curr Opin Rheumatol. 2014 Sep;26(5):520-7. doi: 10.1097/BOR.0000000000000096

8. Kroese FG, Abdulahad WH, Haacke E, et al. B-cell hyperactivity in primary Sjö gren's syndrome. Expert Rev Clin Immunol. 2014;10:483-99. doi: 10.1586/1744666X.2014.891439

9. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis. 2003;62(2):ii55-9. doi: 10.1136/ard.62.suppl_2.ii55

10. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjö gren's syndrome: an open-label phase II study. Arthritis Rheum. 2005;52: 2740-50. doi: 10.1002/art.21260

11. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjö gren's syndrome. Arthritis Rheum. 2009;60:3251-6. doi: 10.1002/art.24903

12. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjö gren's Syndrome after two infusions of rituximab (Anti-CD20). Arthritis Rheum. 2007;57: 310-7. doi: 10.1002/art.22536

13. Devauchelle-Pensec V, Morvan J, Rat AC, et al. Effects of rituximab therapy on quality of life in patients with primary Sjö gren's syndrome. Clin Exp Rheumatol. 2011;29(1):6-12.

14. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjö gren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6): 1026-31. doi: 10.1136/annrheumdis-2012-202293

15. St Clair EW, Levesque MC, Prak ET, et al. Rituximab therapy for primary Sjö gren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013; 65:1097-106. doi: 10.1002/art.37850

16. Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjö gren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013 Oct 30;15(5):R172. doi: 10.1186/ar4359

17. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjö gren syndrome with rituximab: results of a randomized, double-blind, placebo controlled pilot study. Ann Rheum Dis. 2008;67:1541-4. doi: 10.1136/ard.2007.083865

18. Meijer J, Meiners P, Vissink A, et al. Effective rituximab treatment in primary Sjö gren's syndrome: A randomised, doubleblind, placebo-controlled trial. Arthritis Rheum. 2010;62:960-8. doi: 10.1002/art.27314

19. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjö gren syndrome with rituximab: A randomized trial. Ann Intern Med. 2014;160(4): 233-42. doi: 10.7326/M13-1085

20. Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjö gren's syndrome. Arthritis Rheum. 2017; 69(7):1440-50. doi: 10.1002/art.40093

21. Meiners PM, Arends S, Meijer JM, et al. Efficacy of retreatment with rituximab in patients with primary Sjö gren's syndrome. Clin Exp Rheumatol. 2015;33:443-4.

22. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297-302. doi: 10.1136/annrheumdis-2011-200460

23. Seror R, Sordet C, Guillevin G, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjö gren's syndrome. Ann Rheum Dis. 2007;66:351-7. doi: 10.1136/ard.2006.057919

24. Nocturne G, Virone A, Ng WF, et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjö gren's syndrome. Arthritis Rheum. 2016 Apr;68(4):977-85. doi: 10.1002/art.39518

25. Verstappen GM, Kroese FG, Meiners PM, et al. B cell depletion therapy normalizes circulating follicular Th cells in primary Sjö gren syndrome. J Rheumatol. 2017 Jan;44(1):49-58. doi: 10.3899/jrheum.160313

26. Scofield RH, Farris AD, Horsfall AC. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum. 1999 Feb;42(2): 199-209. doi: 10.1002/1529-0131(199902)42: 23.0.CO;2-1

27. Verstappen GM, van Nimwegen JF, Vissink A, et al. The value of rituximab treatment in primary Sjö gren's syndrome. Clin Immunol. 2017 Sep;182:62-71. doi: 10.1016/j.clim.2017.05.002

28. Gottenberg GE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjö gren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013 May 24;8(5):e59868. doi: 10.1371/journal.pone.0059868

29. Kormelink TG, Tekstra J, Thurlings RM, et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis. 2010;69:2137-44. doi: 10.1136/ard.2009.126441

30. Pollard RP, Abdulahad WH, Bootsma H, et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjö gren's syndrome. Ann Rheum Dis. 2013;72:2048-50. doi: 10.1136/annrheumdis-2013-203447

31. Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjö gren's syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071

32. Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72. doi: 10.1038/nrrheum.2016.18

33. Delli K, Haacke EA, Kroese FG, et al. Towards personalised treatment in primary Sjö gren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis. 2016 Nov; 75(11):1933-8. doi: 10.1136/annrheumdis2015-208304

34. Haacke EA, Vegt B, Meiners PM, et al. Abatacept treatment of patients with primary Sjö gren's syndrome results in a decrease of germinal centres in salivary gland tissue. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):317-20.

35. Haacke BH, Kroese FGM, Kluin P, et al. Salivary Gland FcRL4+ B-Cells Are a Potential Source of Progenitor Cells for MALT Lymphoma in Primary Sjö gren's Syndrome – ACR Meeting Abstracts. Arthritis Rheum. 2015;Suppl 10:67.

36. Hamza N, Bootsma H, Yuvaraj S, et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjö gren's syndrome after B cell depletion therapy. Ann Rheum Dis. 2012;71: 1881-7. doi: 10.1136/annrheumdis-2011-201189

37. Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67:917-25. doi: 10.1136/ard.2007.080960

38. Burlage FR, Pijpe J, Coppes RP, et al. Variability of flow rate when collecting stimulated human parotid saliva. Eur J Oral Sci. 2005;113:386-90. doi: 10.1111/j.1600-0722.2005.00241.x

39. Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, et al. Ultrasound assessment of salivary glands in patients with primary Sjö gren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis. Biologics. 2007 Sep;1(3):311-9.

40. Jousse-Joulin S, Devauchelle-Pensec V, Cornec D. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjö gren's Syndrome. Arthritis Rheum. 2015 Jun;67(6):1623-8. doi: 10.1002/art.39088

41. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea. 2004;23:272-85. doi: 10.1097/00003226-200404000-00010

42. Rose-Nussbaumer J, Lietman TM, Shiboski CH, et al. Inter-grader Agreement of the Ocular Staining Score in the Sjö gren's International Clinical Collaborative Alliance (SICCA) Registry. Am J Ophthalmol. 2015; 160:1150-3. doi: 10.1016/j.ajo.2015.08.021

43. Cornec D, Devauchelle-Pensec V, Mariette XS, et al. Development of the Sjö gren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology. 2015;54:1699-708. doi: 10.1093/rheumatology/kev114

44. Benucci M, Manfredi M, Puttini PS, et al. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? Autoimmun Rev. 2010; 9:801-3. doi: 10.1016/j.autrev.2010.07.006

45. Anolik HN, Campbell D, Felgar RE, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48:455-9. doi: 10.1002/art.10764

46. Cornec D, Costa S, DevauchellePensec V, et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjö gren's syndrome. J Autoimmun. 2016; 67:102-10. doi: 10.1016/j.jaut.2015.11.002

47. Delli K, Haacke EA, Kroese FG, et al. In primary Sjö gren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI. Ann Rheum Dis. 2016 Jun;75(6):e34. doi: 10.1136/annrheumdis-2016-209317

48. Letaief H, Lukas C, Barnetche T, et al. Efficacy and safety of biological DMARDs modulating B cells in primary Sjö gren's syndrome: Systematic review and meta-analysis. Joint Bone Spine. 2018 Jan;85(1):15-22. doi: 10.1016/j.jbspin.2017.06.004

49. Aure MH, Arany S, Ovitt CE. Salivary Glands: Stem Cells, Self-duplication, or Both? J Dent Res. 2015;94(11):1502-7. doi: 10.1177/0022034515599770

50. Tarn JR, Howard-Tripp N, Lendrem DW, et al. Symptom-based stratification of patients with primary Sjö gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 2019;1:e85-94.

51. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjö gren's syndrome with EULAR primary Sjö gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016 Feb;75(2): 382-9.

52. Bezzina OM, Gallagher P, Mitchell S, et al. Subjective and Objective Measures of Dryness Symptoms in Primary Sjö gren's Syndrome – Capturing the discrepancy. Arthritis Care Res (Hoboken). 2017 Nov; 69(11):1714-23. doi: 10.1002/acr.23165

53. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjö gren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjö gren's syndrome. Ann Rheum Dis. 2010;69:1103-9. doi: 10.1136/ard.2009.110619


Для цитирования:


Торгашина А.В. Эффективность ритуксимаба при железистых формах болезни Шёгрена по результатам международных клинических исследований. Современная ревматология. 2020;14(1):85-92. https://doi.org/10.14412/1996-7012-2020-1-85-92

For citation:


Torgashina A.V. Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials. Modern Rheumatology Journal. 2020;14(1):85-92. (In Russ.) https://doi.org/10.14412/1996-7012-2020-1-85-92

Просмотров: 69


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)